

BIOSYNTECH, INC.
MATERIAL CHANGE REPORT

Pursuant to: Part 7 of National Instrument 51-102.

Item 1. Reporting Issuer:

The name of the reporting issuer is BioSyntech, Inc. Its principal office is located at 475 Armand-Frappier Blvd, Laval, Quebec H7V 4B3, and its telephone number is (450) 686-2437.

Item 2. Date of Material Change:

February 8, 2007.

Item 3. Press release:

A press release was issued in Montreal, Quebec on February 8, 2007 with respect to the material change.

Item 4. Summary of Material Change:

BioSyntech announced the start of recruitment into its Canadian pivotal clinical trial for BST-DermOn(TM), a medical device designed to repair chronic wounds.

Item 5. Full Description of Material Change:

See attached press release

Item 6. Reliance on: Section 75(3) of the *Securities Act* (Ontario) and Section 73(1) of the *Securities Act* (Quebec)

Not applicable.

Item 7. Omitted Information:

No information has been omitted in respect of the material change.

Item 8.

Senior Officers:

Further information with respect to the material change described in this material change report may be obtained from:

Claude LeDuc
President & CEO
Biosynotech, Inc.
at (450) 686-2437

Item 9.

Statement of Senior Officer:

The foregoing accurately discloses the material change referred to herein.

DATED at Montreal, Quebec, this 15 day of February, 2007.

BIOSYNTECH, INC.

Per: (signed: "Claude LeDuc")
Claude LeDuc, President & CEO